ENDRA Life Sciences Further Strengthens TAEUS® System Intellectual Property Protection with Issuance of 21st U.S. Patent
13 October 2021 - 11:00PM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been
issued U.S. Patent 11147067 (the ‘067 patent) titled, “Method And
System For Monitoring Tissue Temperature” from the United States
Patent & Trademark Office.
The ‘067 patent relates to a novel method and system for
monitoring tissue temperature during surgical procedures using
ENDRA’s TAEUS® system. ENDRA expects that TAEUS® will be effective
for both thermotherapy and cryotherapy procedures. The recently
issued patent complements U.S. Patent 10631734, also titled,
“Method And System For Monitoring Tissue Temperature,” which was
issued on April 28, 2020. Each of these patents utilize different
methods to achieve similar results.
“The issuance of this new patent represents the continued
advancement of the development of our optimized ultrasound and
thermoacoustic imaging systems for a wide variety of applications
where no practical tools currently exist, including for
Non-Alcoholic Fatty Liver Disease (NAFLD)," explained ENDRA's Chief
Executive Officer Francois Michelon. "Our IP portfolio continues to
grow and currently stands at 87 assets, which we define as patents
issued, filed or in preparation. As we advance TAEUS® commercial
launch plans for Europe and await U.S. regulatory response, it is
essential to protect our intellectual property in priority global
markets.”
TAEUS® is currently cleared for sale in countries that recognize
the CE mark, including those in the European Union, and a 510(k)
application has been submitted to the U.S. Food and Drug
Administration.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver
conditions that affect over one billion people globally, and for
which there are no practical diagnostic tools. Beyond the liver,
ENDRA is exploring several other clinical applications of TAEUS®,
including visualization of tissue temperature during energy-based
surgical procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as "believe," "expect," "may,"
"will," "should," "could," "seek," "intend," "plan," "goal,"
"estimate," "anticipate" or other comparable terms. Examples of
forward-looking statements for ENDRA include, among others,
estimates of the timing of future events and achievements, such as
the expectations regarding the transition of leadership of ENDRA’s
finance function, and expectations concerning ENDRA's business
strategy, which may be affected by risks related to the impact of
COVID-19 on its business plan, its ability to find and maintain
development partners, market acceptance of its technology and the
amount and nature of competition in its industry, its ability to
protect its intellectual property, and other risks and
uncertainties described in its filings with the Securities and
Exchange Commission. Forward-looking statements involve inherent
risks and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements as a result
of various factors including, among others, our ability to develop
a commercially feasible technology; receipt of necessary regulatory
approvals; the impact of COVID-19 on our business plans; our
ability to find and maintain development partners, market
acceptance of our technology and the amount and nature of
competition in our industry; our ability to protect our
intellectual property; and the other risks and uncertainties
described in ENDRA's filings with the Securities and Exchange
Commission. The forward-looking statements made in this news
release speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211013005096/en/
Company: Irina Pestrikova Senior Director, Finance
investors@endrainc.com www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations
(310) 691-7100 YBriggs@lhai.com
Media: Jules Abraham JQA Partners, Inc. (917) 885-7378
jabraham@jqapartners.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2024 to May 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From May 2023 to May 2024